BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company

Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids

The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms

FDA endorses Relmada’s registrational strategy for bladder cancer therapy

ISVIR 2026 showcases cutting-edge interventional radiology in India

Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine

Merck scores FDA nod for TGT drug Pimicotinib, promising new hope for patients

The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes

FDA nod to first-ever treatment for fatal pediatric Menkes disease

US healthcare costs spark push for Ayurveda integration

BioMed X launches Harvard pilot to connect academia and pharma

Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements

Organon strikes deal with Daiichi Sankyo to launch breakthrough cholesterol drug in Northern Europe

This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway

AstraZeneca appoints Laura Colon as new President of Spain

After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets